ESC 365 - Impact of clopidogrel metabolizer status on platelet aggregation and association with outcomes in AF patients undergoing PCI

ESC2025 Premium Access

Impact of clopidogrel metabolizer status on platelet aggregation and association with outcomes in AF patients undergoing PCI

Session: New perspectives in cardiology (2) - Antithrombotic pharmacotherapy

Topic: Antiplatelet Drugs

Speaker: Mrs D. Gjermeni (Stanford, US)

Event: ESC Congress 2025

Congress Presentation

Add to my library

About the speaker

Mrs Diona Gjermeni

Stanford Center for Clinical Research, Stanford (United States of America)

0 follower

10 more presentations in this session

Discussant - Antithrombotic pharmacotherapy

Safety and efficacy of factor XI/XIa inhibitors compared to factor Xa inhibitors for stroke prophylaxis in atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials

Speaker: Mr G. Arrighini (Bologna, IT)

Sex differences in dual antiplatelet therapy de-Escalation strategies in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis

Speaker: Doctor G. Occhipinti (Barcelona, ES)

Direct oral anticoagulants versus warfarin or vitamin k antagonists in patients with left-sided bioprosthetic valves and atrial fibrillation: a meta-analysis

Speaker: Doctor A. Abdelaziz (Damietta, EG)

Platelet reactivity of clopidogrel and aspirin with or without omeprazole in diabetes mellitus and coronary artery disease in thailand: a randomised double-blind placebo-controlled cross-over trial

Speaker: Doctor M. Thungthienthong (Bangkok, TH)

Access the full session

New perspectives in cardiology (2) - Antithrombotic pharmacotherapy

Speakers: Mrs D. Gjermeni, Mr G. Arrighini, Doctor G. Occhipinti, Doctor A. Abdelaziz, Doctor M. Thungthienthong

About the event

ESC Congress 2025

29 August - 1 September 2025

Sessions Presentations

Congress

ESC 365 is supported by

bristol-myers-squibb

Explore sponsored resources

novartis

Explore sponsored resources